New Investing App Saves Investors an Average of $97,347
Most people are terrible at buying and selling stocks at the right time, but the TradeSmith app takes the emotion out of investing.

Our back test shows, the average investor would've made $97,347 more just by using the TradeSmith app analyzer software.

Check out this FREE video.
>>>
Giovanni Caforio, insider at Bristol-Myers Squibb

Giovanni Caforio Insider Information

Giovanni Caforio, M.D. has been chief executive officer of Bristol Myers Squibb since May 2015 and has been serving on the company’s Board of Directors since June 2014. In May 2017, he assumed the role of chairman of the board.

As CEO, Giovanni has led the company’s focus on researching and developing transformational medicines, which includes a leading portfolio of immunotherapies that are fundamentally changing the way cancer is treated. Under his leadership, BMS is evolving its operating model, in order to increase speed and competitiveness. 

With a background as a physician, Giovanni has helped strengthen the company’s patient-focused culture -- one driven by innovation, speed, accountability and passion. As a leader, he is focused on the business value of a company culture that promotes and rewards diversity and inclusion. 

Prior to becoming CEO, Giovanni served as chief operating officer with responsibility for leading a fully integrated worldwide commercial organization and the companywide functions of Enterprise Services and Global Manufacturing & Supply. This was preceded by his work as the company’s chief commercial officer. 

Giovanni joined Bristol Myers Squibb in 2000 as vice president and general manager, Italy, in the Worldwide Medicines Group. He assumed added responsibility for Greece and Israel in 2001, and for South East Europe in 2003. In 2004, he was appointed senior vice president, European Marketing and Brand Commercialization. In 2007, he relocated to the US to assume the role of senior vice president, U.S. Oncology. In 2010, he was named senior vice president, Global Commercialization, Oncology and Immunology, before becoming president of the company’s U.S. organization in 2011. Prior to joining Bristol Myers Squibb, Giovanni spent 12 years with Abbott Laboratories in a number of leadership positions. 

Born and educated in Italy, Giovanni received his M.D. from the University of Rome. 

What is Giovanni Caforio's net worth?

The estimated net worth of Giovanni Caforio is at least $42.08 million as of June 13th, 2022. Dr. Caforio owns 551,104 shares of Bristol-Myers Squibb stock worth more than $42,082,301 as of June 30th. This net worth evaluation does not reflect any other investments that Dr. Caforio may own. Additionally, Dr. Caforio receives a salary of $5,820,000.00 as CEO at Bristol-Myers Squibb. Learn More about Giovanni Caforio's net worth.

How old is Giovanni Caforio?

Dr. Caforio is currently 57 years old. There are 7 older executives and no younger executives at Bristol-Myers Squibb. Learn More on Giovanni Caforio's age.

What is Giovanni Caforio's salary?

As the CEO of Bristol-Myers Squibb, Dr. Caforio earns $5,820,000.00 per year. Learn More on Giovanni Caforio's salary.

How do I contact Giovanni Caforio?

The corporate mailing address for Dr. Caforio and other Bristol-Myers Squibb executives is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. Bristol-Myers Squibb can also be reached via phone at (212) 546-4000 and via email at [email protected] Learn More on Giovanni Caforio's contact information.

Has Giovanni Caforio been buying or selling shares of Bristol-Myers Squibb?

Over the course of the past ninety days, Giovanni Caforio has sold $2,221,200.00 of Bristol-Myers Squibb stock. 0 shares of the company's stock in a transaction dated Thursday, June 30th. Learn More on Giovanni Caforio's trading history.

Who are Bristol-Myers Squibb's active insiders?

Bristol-Myers Squibb's insider roster includes Mark Alles (CEO), Christopher Boerner (EVP), Giovanni Caforio (CEO), Adam Dubow (SVP), Joseph Eid (SVP), John Elicker (EVP), David Elkins (CFO), Sandra Leung (EVP), Dinesh Paliwal (Director), Karen Santiago (SVP), Louis Schmukler (EVP), Rupert Vessey (EVP), and Paul von Autenried (EVP). Learn More on Bristol-Myers Squibb's active insiders.

Are insiders buying or selling shares of Bristol-Myers Squibb?

During the last year, insiders at the biopharmaceutical company sold shares 11 times. They sold a total of 421,075 shares worth more than $28,776,795.70. The most recent insider tranaction occured on June, 13th when CEO Giovanni Caforio sold 30,000 shares worth more than $2,221,200.00. Insiders at Bristol-Myers Squibb own 0.1 % of the company. Learn More about insider trades at Bristol-Myers Squibb.

Information on this page was last updated on 6/13/2022.

Giovanni Caforio Insider Trading History at Bristol-Myers Squibb

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/13/2022Sell30,000$74.04$2,221,200.00551,104View SEC Filing Icon  
3/21/2022Sell25,000$71.52$1,788,000.00View SEC Filing Icon  
2/24/2022Sell30,000$67.00$2,010,000.00View SEC Filing Icon  
9/20/2021Sell25,000$60.64$1,516,000.00View SEC Filing Icon  
3/22/2021Sell25,000$62.20$1,555,000.00528,980View SEC Filing Icon  
8/31/2020Sell39,840$62.70$2,497,968.00445,584View SEC Filing Icon  
5/3/2016Sell34,594$71.31$2,466,898.14132,263View SEC Filing Icon  
2/17/2016Sell12,040$63.58$765,503.2076,738View SEC Filing Icon  
9/15/2014Sell26,691$49.87$1,331,080.17View SEC Filing Icon  
2/24/2014Sell41,563$54.44$2,262,689.7249,753View SEC Filing Icon  
5/31/2013Sell10,538$47.06$495,918.28View SEC Filing Icon  
5/23/2013Sell26,647$46.29$1,233,489.63View SEC Filing Icon  
2/27/2013Sell12,150$37.08$450,522.00View SEC Filing Icon  
See Full Table

Giovanni Caforio Buying and Selling Activity at Bristol-Myers Squibb

This chart shows Giovanni Caforio's buying and selling at Bristol-Myers Squibb by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Bristol-Myers Squibb Company Overview

Bristol-Myers Squibb logo
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Read More

Today's Range

Now: $76.68
Low: $76.30
High: $77.62

50 Day Range

MA: $76.09
Low: $72.62
High: $79.98

2 Week Range

Now: $76.68
Low: $53.22
High: $80.59

Volume

345,094 shs

Average Volume

14,787,620 shs

Market Capitalization

$163.26 billion

P/E Ratio

27.76

Dividend Yield

2.74%

Beta

0.49
Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.